BRNS logo

Barinthus Biotherapeutics (BRNS) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United Kingdom

IPO:

30 April 2021

Indexes:

Not included

Description:

Barinthus Biotherapeutics (BRNS) focuses on developing innovative biopharmaceuticals. The company specializes in creating advanced therapies for various diseases, leveraging cutting-edge research and technology to improve patient outcomes and enhance healthcare solutions. Their mission is to transform medical treatments through scientific excellence and collaboration.

Key Details

Price

$0.95

Annual Revenue

$802.00 K(-98.21% YoY)

Annual EPS

-$1.91(-1464.29% YoY)

Annual ROE

-34.10%

Beta

0.49

Events Calendar

Earnings

Next earnings date:

Mar 20, 2025

Recent quarterly earnings:

Nov 06, 2024

Recent annual earnings:

Mar 20, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

19 Nov '24 HC Wainwright & Co.
Buy
08 Nov '24 HC Wainwright & Co.
Buy
01 Oct '24 HC Wainwright & Co.
Buy
26 Sept '24 HC Wainwright & Co.
Buy
13 Aug '24 Alliance Global Partners
Buy
12 Aug '24 HC Wainwright & Co.
Buy
13 June '24 Barclays
Overweight
07 June '24 HC Wainwright & Co.
Buy
16 May '24 HC Wainwright & Co.
Buy
22 Apr '24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer
Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer
Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer
BRNS
globenewswire.com25 November 2024

OXFORD, United Kingdom and GERMANTOWN, Md., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio”), today announced the promotion of Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer (CSO), effective as of December 1, 2024. Dr. Lynn succeeds Nadège Pelletier, Ph.D. who decided to pursue alternative opportunities closer to home after having served as Barinthus Bio's CSO since early 2023. Barinthus Bio is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that guide T cells to control disease.

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
BRNS
globenewswire.com15 November 2024

Eight participants achieved HBsAg loss at any time. Two participants met criteria for functional cure.

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
BRNS
globenewswire.com15 November 2024

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with

Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results
BRNS
globenewswire.com06 November 2024

OXFORD, United Kingdom, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that guide T cells to control disease, provided an overview of business updates and announced financial results for the third quarter of 2024. “We continue our strong execution on our clinical trials, completing enrollment in the HBV003 trial of VTP-300 in chronic hepatitis B, and advancing VTP-1000 in celiac disease into the clinic with the first in human study of the novel SNAP-TI platform,” said Dr. Leon Hooftman, Chief Medical Officer of Barinthus Bio.

FAQ

  • What is the primary business of Barinthus Biotherapeutics?
  • What is the ticker symbol for Barinthus Biotherapeutics?
  • Does Barinthus Biotherapeutics pay dividends?
  • What sector is Barinthus Biotherapeutics in?
  • What industry is Barinthus Biotherapeutics in?
  • What country is Barinthus Biotherapeutics based in?
  • When did Barinthus Biotherapeutics go public?
  • Is Barinthus Biotherapeutics in the S&P 500?
  • Is Barinthus Biotherapeutics in the NASDAQ 100?
  • Is Barinthus Biotherapeutics in the Dow Jones?
  • When was Barinthus Biotherapeutics's last earnings report?
  • When does Barinthus Biotherapeutics report earnings?
  • Should I buy Barinthus Biotherapeutics stock now?

What is the primary business of Barinthus Biotherapeutics?

Barinthus Biotherapeutics (BRNS) focuses on developing innovative biopharmaceuticals. The company specializes in creating advanced therapies for various diseases, leveraging cutting-edge research and technology to improve patient outcomes and enhance healthcare solutions. Their mission is to transform medical treatments through scientific excellence and collaboration.

What is the ticker symbol for Barinthus Biotherapeutics?

The ticker symbol for Barinthus Biotherapeutics is NASDAQ:BRNS

Does Barinthus Biotherapeutics pay dividends?

No, Barinthus Biotherapeutics does not pay dividends

What sector is Barinthus Biotherapeutics in?

Barinthus Biotherapeutics is in the Healthcare sector

What industry is Barinthus Biotherapeutics in?

Barinthus Biotherapeutics is in the Biotechnology industry

What country is Barinthus Biotherapeutics based in?

Barinthus Biotherapeutics is headquartered in United Kingdom

When did Barinthus Biotherapeutics go public?

Barinthus Biotherapeutics's initial public offering (IPO) was on 30 April 2021

Is Barinthus Biotherapeutics in the S&P 500?

No, Barinthus Biotherapeutics is not included in the S&P 500 index

Is Barinthus Biotherapeutics in the NASDAQ 100?

No, Barinthus Biotherapeutics is not included in the NASDAQ 100 index

Is Barinthus Biotherapeutics in the Dow Jones?

No, Barinthus Biotherapeutics is not included in the Dow Jones index

When was Barinthus Biotherapeutics's last earnings report?

Barinthus Biotherapeutics's most recent earnings report was on 6 November 2024

When does Barinthus Biotherapeutics report earnings?

The next expected earnings date for Barinthus Biotherapeutics is 20 March 2025

Should I buy Barinthus Biotherapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions